MaxCyte Inc. (MXCT)
MXCT trades on Nasdaq in Health Care, Biotechnology: Commercial Physical & Biological Resarch. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$0.9643
-3.08% on the day
Market cap
$99.5M
Micro cap
Revenue · 2025
$33.0M
-14.5% on 2024
Net income · 2025
-$44.6M
-135.1% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | MXCT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001287098 |
| SEC industry code | Services-Commercial Physical & Biological Research |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $33.0M |
| Net income | -$44.6M |
| Operating income | -$51.9M |
| Net margin | -135.1% |
| Operating margin | -157.1% |
| Revenue growth | -14.5% |
| Cash | $20.1M |
| Total assets | $202.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 3.0× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B4 | 2021-07-30 |
| Latest annual report | 10-K | 2026-03-25 |
| Latest quarterly / interim | 10-Q | 2026-08-13 |
| Latest current report FORM 8-K | 8-K | 2026-10-14 |
| Latest proxy DEFA 14A | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 334 recent filings. All filings on EDGAR.
Peers in Biotechnology: Commercial Physical & Biological Resarch
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ONMD | OneMedNet Corp | $4.02 | +2.29% | $24.2M |
| NRC | NRC Health | $20.17 | -1.18% | $446.2M |
| OABI | OmniAb Inc. | $4.70 | -1.47% | $683.3M |
| ABSI | Absci Corporation | $9.10 | -5.89% | $1.6B |
| BIAF | bioAffinity Technologies Inc. | $3.63 | -7.05% | $4.7M |
| ISPC | iSpecimen Inc. | $1.08 | 0.00% | $2.7M |
| ICLR | ICON plc | $164.34 | -0.04% | $12.6B |
| CRL | Charles River Laboratories International Inc. | $299.02 | -0.94% | $14.3B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier